Anixa Biosciences granted patent for breast cancer vaccine technology in Mexico

Anixa Biosciences (ANIX) announced that the Mexican Institute of Industrial Property – the IMPI – has issued a Notice of Allowance for a new patent related to its breast cancer vaccine technology. This patent, exclusively licensed from Cleveland Clinic, will provide composition of matter protection for the company’s novel approach to breast cancer treatment and prevention in Mexico. The Mexican patent complements patents issued in the United States and other global jurisdictions. Anixa’s vaccine is based on immunizing against human alpha-lactalbumin, a protein associated with lactation that is aberrantly expressed in certain types of breast cancer. This “retired” protein strategy, developed at Cleveland Clinic and licensed exclusively to Anixa, aims to selectively prime the immune system to prevent tumor formation while avoiding harm to normal tissue.